Loading...
Loading...
VIR| Name | Value |
|---|---|
| Revenues | 56.4M |
| Cost of Revenue | 4.6M |
| Gross Profit | 51.8M |
| Operating Expense | 104.3M |
| Operating I/L | -52.5M |
| Other Income/Expense | 15.1M |
| Interest Income | 21.3M |
| Pretax | -65.0M |
| Income Tax Expense | 0.3M |
| Net Income/Loss | -65.3M |
Vir Biotechnology, Inc. is a commercial-stage immunology company specializing in the development of therapeutic products for serious infectious diseases. Their product portfolio includes Sotrovimab (VIR-7832) for treating and preventing COVID-19, VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, and VIR-1111 for HIV prevention. The company generates revenue through the sale of these therapeutic products, as well as through grant agreements with organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health, collaboration and license agreements with pharmaceutical companies, and manufacturing agreements with partners like Samsung Biologics Co., Ltd.
